ESG Data
ESG Data Focus
1. Environment
Recognizing that social and environmental problems caused by climate change are urgent issues, we collect and analyze the required data in accordance with the way of the Task Force on Climate-related Financial Disclosures (TCFD). The current situation is as follows.
Governance
Governance
At the company, the Sustainability Committee formulates and monitors strategies on climate change and reports the details to the Board of Directors and the Management Committee.
Strategy
Strategy
All of the CO2 that the group, which is in a service industry, emits originates from electricity, which is used in the leased offices where the company is based. In light of this situation, we work on energy-saving activities at each office and will consider whether or not it is possible to switch to electricity derived from renewable energy at each building we are in.
In addition, based on the above situation, we have evaluated that the impact on business of the transition risks related to climate change is not large at the company, but we have recognized the following as the major physical risks and opportunities. We have already formulated a BCP for the following physical risks, and will implement reviews and training continuously.
| Physical risks | Opportunities |
|---|---|
| Decline in the level of operations at business bases due to a sudden disaster | Increase in customers’ (pharmaceutical companies) development of new drugs for new diseases |
| Spread of disease |
Risk management
Risk management
The integration of climate change risks into the company-wide risk management system is scheduled for completion by the report for next fiscal year.
Indicators and targets
Indicators and targets
We will continue to consider climate change indicators and targets in the future. Our actual GHG emissions are as follows.
| GHG emissions (t-CO2) | 2022 | 2021 | 2020 |
| Scope１ | 0 | 0 | 0 |
| Scope 2 consolidated | 384.2 | 396.7 | 415.7 |
| Scope 2 non-consolidated(Japan Only) |
326.1 | 341.7 | 364.8 |
* The company has no emissions fall under Scope 1. The company’s Scope 2 emissions are due to the use of power purchased from external providers. These were calculated using market standards.
2. Social
For the company, which provides services globally as a pharmaceutical development professional, our employees are the source of value creation. In order to expand business globally and increase corporate value sustainably in the rapidly changing healthcare industry, it is important that employees with diverse experience can demonstrate their abilities and characteristics to the maximum and continue to succeed.
To that end, we will develop a workforce who can make rapid progress as professionals in an era of change, and we will provide opportunities that enable each and every employee to demonstrate their abilities and characteristics to the maximum and pursue their own wellbeing.
Moreover, we will promote the development of the next generation of executives who can realize sustainable growth as a global company.
The Diversity of Core Employees:
a. Women
a. Women
【Headquarters (Japan)】
| End of Mar 2023 | End of Mar 2022 | End of Mar 2021 | |
| Ratio of Female Employees | 62.9% | 61.6% | 44.4% |
| Ratio of Female Managers | 44.2% | 42.6% | 19.4% |
| Ratio of Female Executive Officers | 16.7% | 16.7% | 16.7% |
【Consolidated (Group)】
| End of Mar 2023 | End of Mar 2022 | End of Mar 2021 | |
| Ratio of Female Employees | 68.4% | 67.5% | 58.6% |
| Ratio of Female Managers | 59.7% | 56.9% | 36.5% |
| Ratio of Female Executive Officers | 31.8% | 28.6% | 25.0% |
b. Foreign Nationals
b. Foreign Nationals
Approximately 50% of the group’s 759 employees (as of March 31, 2023) are locally hired employees residing overseas, and most of the key positions in the overseas group companies are occupied by highly qualified local human resources. In addition, our company is promoting the hiring of human resources regardless of nationality at our headquarters in Japan. As of the end of March 2023, the ratio of foreign nationals to all employees at the Japanese headquarters was 3.6%. In addition, the ratio of foreign employees in managerial positions was 1.1%.
c. Mid-career Hires
c. Mid-career Hires
As of the end of March 2023, the ratio of mid-career hires to all employees at the Japanese headquarters was 42.3%. The ratio of mid-career hires for executive officers is 100%, and the ratio of mid-career hires for managers is 71.6%. As of the end of March 2023, the ratio of mid-career hires to all employees in the entire group was 66.8%. The ratio of mid-career hires for executive officers was 100%, and the ratio of mid-career hires for managers was 81.8%.
Successful clinical trials start with Linical.
Don’t let the complex clinical development journey hold you back. With Linical, you can overcome obstacles, save valuable time and money, and reach your goals.
01 Request a proposal
We start by listening to your needs and understanding your goals to ensure we’re the right CRO for you.
02 Get a plan for success
We propose solutions that proactively tackle obstacles, optimize your trial design, and position you for success every step of the way.
03 Execute with confidence
We’ll guide you through each phase of the process, offering personalized support and a full range of services to help you achieve a successful trial. We are not a “one size fits all” CRO.
.webp?width=518&height=780&name=cta-img%20(2).webp)